20:26 , Jul 18, 2018 |  BC Innovations  |  Emerging Company Profile

Ministring theory in practice

Mediphage Bioceuticals Inc.’s ministrings have safety, manufacturing and other advantages that could give conventional plasmids and related vectors a run for their money in the gene therapy space. The newco’s ministrings are linear DNAs with covalently...
23:56 , Dec 19, 2017 |  BC Extra  |  Politics & Policy

Federal funding ban lifted for pathogen research

NIH said a three-year long federal pause on funding for gain of function (GOF) research on pathogens has been lifted. The green light came after HHS published a framework Tuesday to guide agency funding decisions...
22:57 , Jun 29, 2017 |  BC Innovations  |  Product R&D

Drop the MIC

Two start-ups have joined the wave of companies harnessing NK cell biology to generate new immunotherapies for cancer by focusing on the relatively unexplored ligands for the NK cell receptor NKG2D. Having laid low for...
19:49 , Mar 3, 2017 |  BC Week In Review  |  Company News

National Research Council Canada, Helix deal

NRC granted Helix worldwide rights to compound 2A3 for cancer indications. The license grants Helix the right to use the antibody in multiple systems, including CAR T cells, in combination with conjugates of the biotech's...
08:00 , Nov 13, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Kai-Jye Lou and Stephen Parmley, Senior Writers, and Mark Zipkin, Staff Writer  Tankyrase translation   With a few pharmas entering the search for tankyrase inhibitors for cancer, Merck KGaA is hedging its bets by joining forces with The...
08:00 , Feb 4, 2013 |  BC Week In Review  |  Company News

AvidBiologics, National Research Council (NRC) Canada deal

AvidBiologics partnered with the NRC to jointly develop three antibody-drug conjugates (ADC) against undisclosed targets to treat cancer. The antibodies were generated as part of the NRC's integrated therapeutic antibody development (ITAD) initiative. AvidBiologics said...
07:00 , Sep 3, 2012 |  BioCentury  |  Strategy

Back to School: Science & austerity

We have entered an age of austerity that, given the fecklessness of the political classes, won't end any time soon. Against that backdrop, the global science community must decide how to succeed with less money. Major...
00:42 , Nov 4, 2011 |  BC Extra  |  Clinical News

Report calls for new disease 'taxonomy'

The National Research Council issued a report calling for the creation of a new disease "taxonomy" that classifies diseases based on molecular biology in addition to traditional physical signs and symptoms. The report, sponsored by...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Clinical News

NRC-AN-019 regulatory update

FDA granted Orphan Drug designation for Natco's NRC-AN-019 to treat brain cancer, pancreatic cancer and chronic myelogenous leukemia (CML). The compound is in an Indian Phase I trial. Natco Pharma Ltd. (BSE:NATCO; NSE:NATCOPHARM), Hyderabad, India...
23:49 , Oct 4, 2010 |  BC Extra  |  Politics & Policy

NRC report: Bayh-Dole Act effective

The National Research Council issued a report that concludes the Bayh-Dole Act of 1980, which gave universities control of IP related to the results of federally funded research, has been more effective than the pre-1980...